Posted by Michael Wonder on 03 Aug 2021
FDA approves new Berinert (C1 esterase inhibitor, human (intravenous)) administration kit for increased patient convenience
3 August 2021 - CSL Behring has received U.S. FDA approval for its supplemental request for co-packaging of a convenience administration kit along with its product Berinert, indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema in adult and paediatric patients.
Combination product packaging will improve the patient experience by providing ready-to-go, essential infusion supplies that are more efficiently packaged.
